glp 1 shortage guidance GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care FDA restricts non-approved compounded GLP-1

In Lafayette, GLP-1 programs range from straightforward prescription-only models to comprehensive weight management plans

Frequently Asked Questions Studies suggest many people regain some of the weight after stopping treatment

Participants were adults aged 18-75 years with a BMI 30 or 27.5 kg/m 2 with the presence of obesity-related comorbidities who initiated a weight management program involving semaglutide or tirzepatide

The study assessed drug utilization and temporal changes in treatment options (e.g., SGLT2i, GLP-1 RA) in adults with CKD and type 2 diabetes regarding two time periods: an earlier period (1 January 201230 June 2021) and a later period after the US approval of finerenone (9 July 202130 September 2023), with the latter period representing updated treatment guidelines, changes to CKD drug labeling (e.g., SGLT2i), and the availability of new CKD-protective medications (ESM Fig

Risk of bias results Risk of bias for the included RCTs was evaluated using the Cochrane RoB 2 tool